Press ReleaseAbstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022
Toronto, Canada, April 14, 2022 — Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that an abstract the company submitted has been accepted by American Society of Clinical Oncology (ASCO) for the 2022 ASCO Annual Meeting and will be published in an online supplement of the Journal of Clinical Oncology following the meeting. ASCO will be held in Chicago from June 3-8, 2022.
This year, ASCO received and reviewed more than 6,000 abstracts for the 2022 ASCO Annual Meeting. For more information about the Annual Meeting, please visit: https://conferences.asco.org/am/attend. Per ASCO’s Embargo & Release Information, abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022.